Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Analytics for clinical development strategy: Tools and opportunities
In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their...